1 min read
Therapeutic Antibody Discovery at Antibody Solutions using the OmniAbTM Platform
By Antibody Solutions Research Team on Apr 29, 2018 1:42:00 PM

Antibody Solutions performed its first program in OmniAbTM animals in September of 2012. In our 6.5 year history with OminAb animals we have worked with >1000 animals for 27 clients. The purpose of this poster is to update Antibody Solutions history of work with OmniAb animals with an emphasis on work performed in
Summary
The OmniAb platform continues to bring tangible benefits to OmniAb partners. Additional benefits will be realized through parallel use of multiple B-cell isolation and interrogation platforms.
Download this poster
We invite you to download our poster that details this research study, including our antibody discovery strategy as well as the Spike protein reagents, screening assay formats, and more that we utilized.
Authors
John S. Kenney, Joshua Lowitz, Glen Lin, Jennifer Somera, Leonel Santibanez-Vargas, Catherine Vo, Spencer Alford*, Ryan Kelly*, and Jennifer Cochran*. Antibody Solutions, Sunnyvale, CA, USA & *xCella Biosciences, Menlo Park, CA, USA

Written by Antibody Solutions Research Team
Filter by Keyword
- Posters (20)
- Publications (14)
- therapeutic monoclonal antibodies (4)
- Multi-pass transmembrane (3)
- Transgenic Animals (3)
- multi-meric membrane (3)
- ELISAs (2)
- Human Therapeutic Antibodies (2)
- Hybridoma (2)
- Monoclonal (2)
- SARS-CoV-2 (2)
- APOBEC3G (1)
- ARMER (1)
- ATX-GX (1)
- Alloy Therapeutics (1)
- Antibody Generation (1)
- BRCA2 (1)
- CEM15 (1)
- Cadherin-11 (1)
- Conditioned Media (1)
- Critical Reagents (1)
- Cystine Knot Peptides (1)
- D Protein (1)
- DLL4 (1)
- Fully Human (1)
- HIV-1 (1)
- HSA (1)
- IL-1 alpha (1)
- Immune B-cells (1)
- Immunization (1)
- Knottins (1)
- L-amino acids (1)
- L-selectin (1)
- LAM (1)
- LBAs (1)
- LOXL2 (1)
- McAbs (1)
- OmniAb (1)
- OmniRat (1)
- PNAd (1)
- Secretion Capture Report Web (1)
- Stereochemistry (1)
- Therapeutic Targets (1)
- Tissue Culture (1)
- VEGF-A (1)
- VEGF-C (1)
- VEGF-D (1)
- antibody discovery (1)
- carcinogenesis (1)
- lymphangioleiomyomatosis (1)
- p53 (1)
- pharmacokinetic (PK) (1)
- transgenic H2L2 mice (1)